GlassScriptPhysician profile
Ximena Lopez
NPI 1740316405
$2,140.57
in general payments reported to CMS, 2019-2025
24 companies · $834 in 2025
The $834 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.23 · 2020: $36.37 · 2021: $45.57 · 2022: $29.52 · 2023: $371 · 2024: $811 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981 · Education: $34.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.28 |
| Education | $34.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $362.87 | 2023-2025 | Sogroya, Wegovy |
| Dexcom, INC. | $267.12 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $184.21 | 2023-2025 | |
| Eton Pharmaceuticals, INC. | $164.14 | 2022-2025 | Alkindi, Increlex, Khindivi |
| Azurity Pharmaceuticals, INC. | $149.44 | 2023-2024 | Triptodur, Triptodur, Horizant |
| Tolmar, INC. | $118.85 | 2023-2025 | Fensolvi |
| Merz Pharmaceuticals, LLC | $106.05 | 2023-2024 | Xeomin |
| Tandem Diabetes Care, INC. | $104.31 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Genentech USA, INC. | $102.72 | 2020-2023 | Ocrevus |
| Neurocrine Biosciences, INC. | $100.22 | 2024-2025 | Ingrezza |
| Insulet Corporation | $81.79 | 2025 | Omnipod |
| Biomarin Pharmaceutical INC. | $78.62 | 2024 | |
| Kyowa Kirin, INC. | $75.90 | 2024-2025 | Crysvita |
| Ascendis Pharma Endocrinology INC | $57.62 | 2025 | Skytrofa |
| Pfizer INC. | $42.39 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $32.57 | 2019-2025 | Mounjaro |
| Beta Bionics, INC. | $24.55 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $23.01 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $18.98 | 2024 | |
| Abbott Laboratories | $17.22 | 2024 | Freestyle Libre 3 |
| Soleno Therapeutics, INC. | $14.60 | 2025 | Vykat Xr |
| Tolmar Pharmaceuticals, INC. | $13.39 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ximena Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.